SCALE Biology Act
Summary
The SCALE Biology Act (HR8981) has been introduced and referred to the House Committee on Science, Space, and Technology. At this early stage with no specific funding or policy details available, there is no measurable market impact. The bill's title suggests synthetic biology, but without text or committee action, no tickers can be confidently linked.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8981 is in the earliest legislative stage with no text or funding details available.
- 2.No tickers can be confidently linked due to lack of specific policy mechanisms.
- 3.Market impact is negligible until committee action or bill text emerges.
Market Implications
No market implications at this time. The bill is procedural and lacks the specificity needed to identify affected companies or sectors. Investors should wait for committee action or the release of bill text before assessing potential impacts on synthetic biology or biomanufacturing companies.
Full Analysis
-
On May 21, 2026, Rep. McClain Delaney (D-MD) introduced HR8981, the SCALE Biology Act, in the 119th Congress. The bill was referred to the House Committee on Science, Space, and Technology. With only three actions (introduction and referral) on the same day, the bill is in its earliest procedural stage.
-
The bill's title suggests it may relate to synthetic biology or biomanufacturing, but no funding amount is specified in the available data. Authorization and appropriation details are absent. Without bill text, the money trail cannot be traced.
-
No structural winners or losers can be identified. The bill has one sponsor (a junior member) and three cosponsors, indicating limited initial momentum. The committee referral is standard for science-related legislation.
-
No real market data is provided for this event. The technology sector data listed (CRWD, NVDA, AAPL, etc.) is unrelated to this bill's subject matter.
-
The legislative path requires committee hearings, markup, floor votes in both chambers, and presidential action. At this stage, the bill has no near-term market implications.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
National Security Presidential Memorandum/NSPM-11
This memorandum directs the national security enterprise (including the Department of War, intelligence agencies, and others) to accelerate the adoption, adaptation, and assurance of AI technologies for military and intelligence missions. It mandates updates to DOD Directive 3000.09 on autonomous weapons within 90 days, requires termination of contracts with companies that repeatedly violate policy (e.g., by enabling adversary control or embedding bias), and emphasizes supply chain resilience and multi-vendor sourcing to avoid single-vendor dependencies.
Strengthening Customs Enforcement
This executive order directs the Secretary of Homeland Security to revise customs enforcement regulations within 180 days, requiring importers of record (IORs) to maintain minimum tangible domestic assets or bonding, disclose ownership and business affiliations, and maintain good standing with CBP. It prohibits foreign IORs from filing informal entries for low-value articles and imposes additional bonding and CTPAT validation requirements for foreign IORs on formal entries, aiming to enhance compliance and revenue collection.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.